Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia (AML)

被引：7
|
作者：
Stone, Richard M. [1 ]
DeAngelo, Daniel J. [1 ]
Galinsky, Ilene [1 ]
Kokulis, Caroline [1 ]
Stewart, Jeremy M. [1 ]
McGinnis, Michael [1 ]
Werner, Lillian [2 ]
Letai, Anthony G. [1 ]
Konopleva, Marina Y. [3 ]
Luskin, Marlise [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124966
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3908
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Final Report of a Phase II Trial of Vorinostat, Idarubicin and Cytarabine In Previously Untreated Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
    Garcia-Manero, Guillermo
    Tambaro, Francesco Paolo
    Bekele, Nebiyou
    Jabbour, Elias
    Borthakur, Gautam
    Ravandi, Farhad
    Konopleva, Marina
    Kadia, Tapan
    Cortes, Jorge E.
    Yang, Hui
    Brandt, Mark
    Pierce, Sherry A.
    Newsome, Willie Mae
    Kantarjian, Hagop
    BLOOD, 2010, 116 (21) : 903 - 904
  • [42] High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial
    Schaich, Markus
    Parmentier, Stefani
    Kramer, Michael
    Illmer, Thomas
    Stoelzel, Friedrich
    Roellig, Christoph
    Thiede, Christian
    Haenel, Mathias
    Schaefer-Eckart, Kerstin
    Aulitzky, Walter
    Einsele, Hermann
    Ho, Anthony D.
    Serve, Hubert
    Berdel, Wolfgang E.
    Mayer, Jiri
    Schmitz, Norbert
    Krause, Stefan W.
    Neubauer, Andreas
    Baldus, Claudia D.
    Schetelig, Johannes
    Bornhaeuser, Martin
    Ehninger, Gerhard
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2094 - +
  • [43] Phase I Trial Combining Venetoclax with Cladribine, Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) for Patients with Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms
    Raychaudhuri, Suravi
    Gooley, Ted
    Rasmussen, Allegra
    Quach, Kim
    Gill, Zach
    Halpern, Anna B.
    Appelbaum, Jacob S.
    Ghiuzeli, Cristina Maria
    Hendrie, Paul C.
    Cassaday, Ryan D.
    Walter, Roland B.
    Estey, Elihu
    Percival, Mary-Elizabeth M.
    BLOOD, 2024, 144 : 4288 - 4289
  • [44] High Dose Cytarabine and Clofarabine (HiDAC→CLOF) in Relapsed or Refractory Acute Myeloid Leukemia, a Phase 2 Trial.
    Powell, Bayard
    D'Agostino, Ralph, Jr.
    Levitan, Denise
    Ellis, Leslie Renee
    Lyerly, Susan
    Skiles, Megan
    Manuel, Megan
    Harrelson, Robin
    Kimbrough, Claire
    Hurd, David Duane
    BLOOD, 2008, 112 (11) : 676 - 676
  • [45] Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML).
    DiPersio, John F.
    Erba, Harry Paul
    Larson, Richard A.
    Luger, Selina M.
    Mangan, Kenneth Francis
    Tallman, Martin S.
    Brill, Jeffrey Mark
    Vuagniaux, Gregoire
    Rouits, Elisabeth
    Zanna, Claudio
    Sorensen, J. Mei
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [46] SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA plus V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
    Garcia-Manero, Guillermo
    Othus, Megan
    Pagel, John M.
    Radich, Jerald P.
    Fang, Min
    Rizzieri, David A.
    Marcucci, Guido
    Strickland, Stephen A.
    Litzow, Mark
    Savoie, Mary Lynn
    Medeiros, Bruno C.
    Sekeres, Mikkael A.
    Lin, Tara L.
    Uy, Geoffrey L.
    Powell, Bayard L.
    Kolitz, Jonathan E.
    Larson, Richard A.
    Stone, Richard M.
    Claxton, David F.
    Essell, James
    Luger, Selina
    Mohan, Sanjay R.
    Moseley, Anna
    Appelbaum, Frederick R.
    Erba, Harry P.
    BLOOD, 2016, 128 (22)
  • [47] A phase I trial of liposomal daunorubicin (Daunoxome®) administered with high-dose cytarabine (HiDAC) to patients (pts) with relapsed acute leukemia (AL).
    Cripe, L
    Kneebone, P
    Roberts, L
    Mukwaya, G
    Rutledge, C
    Gordon, M
    BLOOD, 1998, 92 (10) : 233A - 233A
  • [48] A randomized trial of high- versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine
    Bradstock, KF
    Matthews, JP
    Lowenthal, RM
    Baxter, H
    Catalano, J
    Brighton, T
    Gill, D
    Eliadis, P
    Joshua, D
    Cannell, P
    Schwarer, AP
    Durrant, S
    Gillett, A
    Koutts, J
    Taylor, K
    Bashford, J
    Arthur, C
    Enno, A
    Dunlop, L
    Szer, J
    Leahy, M
    Juneja, S
    Young, GAR
    BLOOD, 2005, 105 (02) : 481 - 488
  • [49] Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under age 61.
    Stone, Richard M.
    Fischer, Thomas
    Paquette, Ronald
    Schiller, Gary
    Schiffer, Charles A.
    Ehninger, Gerhard
    Cortes, Jorge
    Kantarjian, Hagop
    DeAngelo, Daniel A.
    Massimini, Georgio
    Li, Xiaoming
    Phillips, Penny
    Giles, Francis
    BLOOD, 2006, 108 (11) : 50A - 51A
  • [50] Phase I/II study of escalating doses of mitoxantrone in a single injection combined with timed sequential therapy with cytarabine and etoposide in patients with refractory or relapsed acute myeloid leukemia (AML).
    Thomas, X
    Cambier, N
    Taksin, AL
    Reman, O
    Vekhoff, A
    Cordonnier, C
    Leblond, V
    Soler-Michel, P
    Ecstein-Fraïssé, E
    Archimbaud, E
    BLOOD, 1999, 94 (10) : 238B - 238B
12345